|
Market Data
Agilent Technologies, Inc.
Agilent Technologies is a global provider of application-focused solutions for the life sciences, diagnostics, and applied chemical markets. The company operates through three primary segments: Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets. Agilent's Life Sciences and Diagnostics segment offers advanced instrumentation and related services for genomics, pathology, and biomolecular analysis, among other areas. The Agilent CrossLab segment provides a comprehensive suite of services, including instrument maintenance, software solutions, and laboratory supplies, supporting customers' operational efficiency. Finally, the Applied Markets segment delivers products in areas such as gas chromatography and spectroscopy, catering to diverse scientific applications. Agilent distributes its offerings through a multi-channel approach, including direct sales and partnerships, ensuring broad market access.
A is currently trading at $118.75, giving Agilent Technologies, Inc. a market cap of 34.16B and a P/E ratio of 26.5. Today's range spans $118.12–$121.81, with shares opening at $120.40 and moving down $1.02 (0.9%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 54/100.
Over the past year A has traded between $98.86 and $160.27 - the current price is +20.1% off the 52-week low and -25.9% from the high. 31 analysts cover the stock with a Buy consensus and a mean 12-month target of $169.67 (range $150.00–$185.00), implying upside of +42.9%.
Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, A (59/100, HOLD, price $118.75, in the lower half of its 52-week range) is waiting for that resolution. Sentiment: neutral at 54/100. The current P/E ratio stands at 26.5. With 34.16B in market cap, the 52-week range of $98.86–$160.27 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $1.41 | - | - |
| Q1'26 | $1.40 | $1.36 | -2.6% |
| Q3'25 | $1.58 | $1.59 | +0.4% |
| Q2'25 | $1.37 | $1.37 | +0.2% |
| Q1'25 | $1.26 | $1.31 | +3.6% |
| Q4'24 | $1.27 | $1.31 | +3.0% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $1.8B | - | - |
| Q1'26 | $1.8B | $1.8B | -2.4% |
| Q3'25 | - | $1.9B | - |
| Q2'25 | - | $1.7B | - |
| Q1'25 | - | $1.7B | - |
| Q4'24 | - | $1.7B | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).